论文部分内容阅读
目的观察比索洛尔对单纯稳定期慢性阻塞性肺疾病(COPD)患者肺功能及相关炎性递质表达的影响。方法将166例COPD患者随机分为观察组和对照组,每组83例。对照组患者给予羧甲司坦片,观察组患者在对照组治疗基础上给予比索洛尔,对比观察2组患者的临床疗效、肺功能情况、6min步行测试结果、相关炎性递质的表达情况和治疗后不良反应发生情况。结果观察组总有效率为97.6%显著高于对照组的86.7%,差异有统计学意义(P<0.05)。治疗后观察组患者FEV1/FVC、FEV1%显著高于治疗前及对照组(P<0.05),对照组治疗前后FEV1/FVC(%)、FEV1%水平比较差异无统计学意义(P>0.05)。2组患者治疗前后FEV1比较差异均无统计学意义(P>0.05)。治疗后2组患者的6min步行测试结果均高于治疗前,且观察组患者显著高于对照组,差异均有统计学意义(P<0.05)。治疗后2组相关炎性递质表达水平均低于治疗前,且观察组低于对照组,差异均有统计学意义(P<0.05)。结论对单纯稳定期COPD患者采用比索洛尔治疗能有效提高临床治疗效果,提高运动耐量、降低相关炎性递质的表达,改善患者肺功能,且不增加不良反应的发生,值得临床进一步推广使用。
Objective To observe the effects of bisoprolol on the lung function and the expression of inflammatory mediators in patients with simple chronic obstructive pulmonary disease (COPD). Methods 166 patients with COPD were randomly divided into observation group and control group, with 83 cases in each group. Patients in the control group were treated with carbocistane tablets. The patients in the observation group were given bisoprolol on the basis of the control group. The clinical efficacy, pulmonary function, 6-minute walking test results and the expression of related inflammatory neurotransmitters were compared between the two groups And the incidence of adverse reactions after treatment. Results The total effective rate in observation group was 97.6%, which was significantly higher than that in control group (86.7%, P <0.05). After treatment, FEV1 / FVC and FEV1% in the observation group were significantly higher than those before treatment and in the control group (P <0.05). There was no significant difference in the FEV1 / FVC (%) and FEV1% . There was no significant difference in FEV1 between the two groups before and after treatment (P> 0.05). The results of 6-minute walking test in both groups after treatment were higher than those before treatment, and the patients in observation group were significantly higher than those in control group (P <0.05). The levels of inflammatory mediators in the two groups after treatment were lower than before treatment, and the observation group was lower than the control group, the difference was statistically significant (P <0.05). Conclusion Bisoprolol can improve the clinical effect, improve the exercise tolerance, reduce the expression of inflammatory mediators, improve the pulmonary function in patients with simple stable COPD and does not increase the incidence of adverse reactions, which is worth further promotion in clinic .